{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-050025","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2024-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.403412+00:00","generated_at":"2026-05-29T03:26:26.623186+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bone Biologics updates ATM offering limit to $832,009 after $846k previously sold","bullets":["Filed prospectus supplement resetting ATM with H.C. Wainwright to max $832,009 in common shares.","Previously sold approximately $846,288 under September 27, 2024 prospectus supplement.","Shares offered under Sales Agreement dated September 27, 2024 with H.C. Wainwright & Co.","Legal opinion from Harter Secrest & Emery LLP on share legality filed as Exhibit 5.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-050025","json":"https://secwatch.observer/filing/0001493152-24-050025.json","markdown":"https://secwatch.observer/filing/0001493152-24-050025.md","text":"https://secwatch.observer/filing/0001493152-24-050025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315224050025/0001493152-24-050025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315224050025/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:26:26.623186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}